Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

BioMarin Pharmaceutical (BMRN)

NASDAQ: BMRN · Biotechnology · Novato, CA

Our rating: Positive

Call changed from Neutral to Positive at $57.13, moderate conviction, November 4, 2026.

Breaks if: The call turns Cautious if reported revenue growth, as disclosed in the next two quarterly filings, decelerates to below 5% on a trailing twelve-month basis — particularly if attributed to volume or pricing pressure in a product touched by the October 2026 invalidation. It would also turn Cautious if free cash flow falls below $500M on an annualized basis in any single quarter, indicating the underlying cash economics have weakened rather than merely diverged from reported earnings on accounting timing.

Key figures

Market value$11.7B
Revenue, last 12 months$3.7B
Net income, last 12 months−$19M
Free cash flow, last 12 months$558M
Price to earningsn/a
Free cash flow yield4.8%
Dividend yield0.0%
Operating margin3.1%
Return on equity−0.3%
Beta to the S&P 5000.59
Volatility, annualized33.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.0B32.0%$-0.63$160M
June 30, 2026$990M19.9%$0.23$139M
March 31, 2026$766M2.8%$0.54$200M
December 31, 2025$875M17.0%$-0.24$59M
September 30, 2025$776M4.1%$-0.16$340M
June 30, 2025$825M15.9%$1.23$168M
March 31, 2025$745M14.8%$0.95$158M
December 31, 2024$747M15.6%$0.65$166M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 45 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.